156 related articles for article (PubMed ID: 37318497)
1. Comparison of different cyclin-dependent kinase inhibitors and KI-67 levels on survival and toxicity in breast cancer treatment.
Bayram E; Selvi O; Köşeci T; Mete B; Yaslıkaya Ş; Paydaş S
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(11):5230-5239. PubMed ID: 37318497
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
3. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
4. CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.
West MT; Smith CE; Kaempf A; Kohs TCL; Amirsoltani R; Ribkoff J; Choung JL; Palumbo A; Mitri Z; Shatzel JJ
Eur J Haematol; 2021 May; 106(5):634-642. PubMed ID: 33527479
[TBL] [Abstract][Full Text] [Related]
5. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
6. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
7. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.
Yıldırım HÇ; Mutlu E; Chalabiyev E; Özen M; Keskinkılıç M; Ön S; Çelebi A; Dursun B; Acar Ö; Kahraman S; Aykan MB; Kaman Ö; Doğan A; Erdoğan AP; Melisa Celayir Ö; Günenç D; Güven DC; Vedat Bayoğlu İ; Yavuzşen T; Hacıbekiroğlu İ; İnanç M; Kılıçkap S; Yalçın Ş; Aksoy S
Breast; 2022 Dec; 66():85-88. PubMed ID: 36208540
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
10. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU
Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723
[TBL] [Abstract][Full Text] [Related]
12. Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Hecht KA; Selby C
Ann Pharmacother; 2019 Feb; 53(2):195-203. PubMed ID: 30079740
[TBL] [Abstract][Full Text] [Related]
13. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
Lee KWC; Lord S; Finn RS; Lim E; Martin A; Loi S; Lynch J; Friedlander M; Lee CK
Breast Cancer Res Treat; 2019 Feb; 174(1):271-278. PubMed ID: 30465154
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.
Hong K; Yao L; Sheng X; Ye D; Guo Y
Oncol Res Treat; 2021; 44(10):557-567. PubMed ID: 34515204
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase 4/6 inhibitors: what have we learnt across studies, therapy situations and substances.
Banys-Paluchowski M; Krawczyk N; Paluchowski P
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):56-66. PubMed ID: 30520756
[TBL] [Abstract][Full Text] [Related]
16. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
Curigliano G; Gómez Pardo P; Meric-Bernstam F; Conte P; Lolkema MP; Beck JT; Bardia A; Martínez García M; Penault-Llorca F; Dhuria S; Tang Z; Solovieff N; Miller M; Di Tomaso E; Hurvitz SA
Breast; 2016 Aug; 28():191-8. PubMed ID: 27336726
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Turner NC; Ro J; André F; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; Huang Bartlett C; Zhang K; Giorgetti C; Randolph S; Koehler M; Cristofanilli M;
N Engl J Med; 2015 Jul; 373(3):209-19. PubMed ID: 26030518
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer.
García-Trevijano Cabetas M; Lucena Martínez P; Jiménez Nácher I; Díaz Almirón M; Zamora Auñón P; Herrero Ambrosio A
Int J Clin Pharm; 2021 Aug; 43(4):893-899. PubMed ID: 33170404
[TBL] [Abstract][Full Text] [Related]
19. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
20. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
